These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 34236953)
1. Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation without Proteasome Inhibition. Penke LRK; Speth J; Wettlaufer S; Draijer C; Peters-Golden M Am J Respir Cell Mol Biol; 2022 Jan; 66(1):23-37. PubMed ID: 34236953 [TBL] [Abstract][Full Text] [Related]
2. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling. Mutlu GM; Budinger GR; Wu M; Lam AP; Zirk A; Rivera S; Urich D; Chiarella SE; Go LH; Ghosh AK; Selman M; Pardo A; Varga J; Kamp DW; Chandel NS; Sznajder JI; Jain M Thorax; 2012 Feb; 67(2):139-46. PubMed ID: 21921091 [TBL] [Abstract][Full Text] [Related]
3. Overcoming interferon (IFN)-γ resistance ameliorates transforming growth factor (TGF)-β-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis. Chang CJ; Lin CF; Lee CH; Chuang HC; Shih FC; Wan SW; Tai C; Chen CL Biochem Pharmacol; 2021 Jan; 183():114356. PubMed ID: 33285108 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Kim A; Seong KM; Kang HJ; Park S; Lee SS Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678 [TBL] [Abstract][Full Text] [Related]
5. Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. Semren N; Habel-Ungewitter NC; Fernandez IE; Königshoff M; Eickelberg O; Stöger T; Meiners S PLoS One; 2015; 10(9):e0136188. PubMed ID: 26340365 [TBL] [Abstract][Full Text] [Related]
6. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma. Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537 [TBL] [Abstract][Full Text] [Related]
7. Nanosized Alumina Particle and Proteasome Inhibitor Bortezomib Prevented inflammation and Osteolysis Induced by Titanium Particle via Autophagy and NF-κB Signaling. Zhang Z; Fu X; Xu L; Hu X; Deng F; Yang Z; Jiang L; Fu T; Zhou P; Song J; Ji P; Huang J; Wu X Sci Rep; 2020 Mar; 10(1):5562. PubMed ID: 32221318 [TBL] [Abstract][Full Text] [Related]
8. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663 [TBL] [Abstract][Full Text] [Related]
9. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Fineschi S; Bongiovanni M; Donati Y; Djaafar S; Naso F; Goffin L; Argiroffo CB; Pache JC; Dayer JM; Ferrari-Lacraz S; Chizzolini C Am J Respir Cell Mol Biol; 2008 Oct; 39(4):458-65. PubMed ID: 18458239 [TBL] [Abstract][Full Text] [Related]
11. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice. van den Brule S; Wallemme L; Uwambayinema F; Huaux F; Lison D J Pharmacol Exp Ther; 2010 Nov; 335(2):472-9. PubMed ID: 20719937 [TBL] [Abstract][Full Text] [Related]
12. Lanatoside C protects mice against bleomycin-induced pulmonary fibrosis through suppression of fibroblast proliferation and differentiation. Nie Y; Zhang D; Jin Z; Li B; Wang X; Che H; You Y; Qian X; Zhang Y; Zhao P; Chai G Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):575-586. PubMed ID: 30854687 [TBL] [Abstract][Full Text] [Related]
13. Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Kinoshita K; Aono Y; Azuma M; Kishi J; Takezaki A; Kishi M; Makino H; Okazaki H; Uehara H; Izumi K; Sone S; Nishioka Y Am J Respir Cell Mol Biol; 2013 Oct; 49(4):536-43. PubMed ID: 23642017 [TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Luo F; Zhuang Y; Sides MD; Sanchez CG; Shan B; White ES; Lasky JA Respir Res; 2014 Apr; 15(1):51. PubMed ID: 24762191 [TBL] [Abstract][Full Text] [Related]
16. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J Cells; 2021 Mar; 10(3):. PubMed ID: 33802801 [TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated Protein Kinase-activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis. Liang J; Liu N; Liu X; Mena JM; Xie T; Geng Y; Huan C; Zhang Y; Taghavifar F; Huang G; Kurkciyan A; Barron V; Jiang D; Noble PW Am J Respir Cell Mol Biol; 2019 Jan; 60(1):41-48. PubMed ID: 30130411 [TBL] [Abstract][Full Text] [Related]
18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
19. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways. Li J; Feng M; Sun R; Li Z; Hu L; Peng G; Xu X; Wang W; Cui F; Yue W; He J; Liu J Toxicol Lett; 2020 Mar; 321():103-113. PubMed ID: 31706003 [TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. Gu Z; Wang X; Cheng R; Cheng L; Zhong Z Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]